Analyzing blood transcriptome profiles for non-human primates, researchers narrowed in on a B cell gene expression signature that appears to coincide with protection from SIV, SHIV, or HIV.
Celsius Therapeutics uses single-cell genomic sequencing and informatics to discover new therapies for autoimmune disease and cancer.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
The effort, called FAIRplus, commenced earlier this year with a budget of €8.2 million, funded by the Innovative Medicine Initiative.
Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.
Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.
Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.
The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.
The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.
GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.